Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Lopes RD, et al. Among authors: califf rm. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019. Am Heart J. 2012. PMID: 22980305 Free PMC article. Clinical Trial.
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: califf rm. Am Heart J. 2005 Oct;150(4):643-9. doi: 10.1016/j.ahj.2005.05.021. Am Heart J. 2005. PMID: 16209958
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: califf rm. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446. JAMA. 2005. PMID: 16287955 Clinical Trial.
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Galla JM, et al. Among authors: califf rm. Am Heart J. 2006 Jan;151(1):16-24. doi: 10.1016/j.ahj.2005.01.045. Am Heart J. 2006. PMID: 16368286
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
Mahaffey KW, Roe MT, Kilaru R, Alexander JH, Van de Werf F, Califf RM, Simoons ML, Topol EJ, Harrington RA. Mahaffey KW, et al. Among authors: califf rm. Eur Heart J. 2007 Feb;28(4):425-32. doi: 10.1093/eurheartj/ehl483. Epub 2007 Jan 31. Eur Heart J. 2007. PMID: 17267458
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB Jr, Peterson ED; PREVENT IV Investigators. Goyal A, et al. Among authors: califf rm. Ann Thorac Surg. 2007 Mar;83(3):993-1001. doi: 10.1016/j.athoracsur.2006.10.046. Ann Thorac Surg. 2007. PMID: 17307447 Clinical Trial.
1,332 results